DDInter1397 DDInter1848
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.[L7712,L7715] A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters. Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class. The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.[L7700,L7742]
Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-microtubule agent, DM1 (a maytansine derivative)--to produce cell cycle arrest and apoptosis. Trastuzumab emtansine is marketed under the brand name Kadcyla and is indicated for use in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment. The FDA label has two precautions. First that trastuzumab emtansine and trastuzumab cannot be interchanged. Second that there is a black box warning of serious side effects such as hepatotoxicity, embryo-fetal toxicity, and cardiac toxicity.
Paroxetine {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Amprenavir
Amprenavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trastuzumab emtansine
Paroxetine {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Cabazitaxel
Cabazitaxel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trastuzumab emtansine
Paroxetine {u} (Compound) causes {v} (Side Effect) Musculoskeletal discomfort
Musculoskeletal discomfort {u} (Side Effect) is caused by {v} (Compound) Amprenavir
Amprenavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trastuzumab emtansine
Paroxetine {u} (Compound) causes {v} (Side Effect) Musculoskeletal discomfort
Musculoskeletal discomfort {u} (Side Effect) is caused by {v} (Compound) Cabazitaxel
Cabazitaxel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trastuzumab emtansine
Paroxetine {u} (Compound) binds {v} (Gene) CYP2B6
CYP2B6 {u} (Gene) is bound by {v} (Compound) Ticlopidine
Ticlopidine {u} may lead to a major life threatening interaction when taken with {v} Trastuzumab emtansine
Paroxetine {u} (Compound) binds {v} (Gene) CYP2B6
CYP2B6 {u} (Gene) is bound by {v} (Compound) Regorafenib
Regorafenib {u} may lead to a major life threatening interaction when taken with {v} Trastuzumab emtansine
Paroxetine {u} (Compound) causes {v} (Side Effect) Transaminases increased
Transaminases increased {u} (Side Effect) is caused by {v} (Compound) Apixaban
Apixaban {u} may lead to a major life threatening interaction when taken with {v} Trastuzumab emtansine
Paroxetine {u} (Compound) causes {v} (Side Effect) Myositis
Myositis {u} (Side Effect) is caused by {v} (Compound) Ticlopidine
Ticlopidine {u} may lead to a major life threatening interaction when taken with {v} Trastuzumab emtansine
Paroxetine {u} (Compound) upregulates {v} (Gene) TSC22D3
TSC22D3 {u} (Gene) is upregulated by {v} (Compound) Ketorolac
Ketorolac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trastuzumab emtansine
Paroxetine {u} (Compound) upregulates {v} (Gene) NFKBIA
NFKBIA {u} (Gene) is downregulated by {v} (Compound) Auranofin
Auranofin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trastuzumab emtansine
Paroxetine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Amprenavir (Compound) and Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Paroxetine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Cabazitaxel (Compound) and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Paroxetine (Compound) causes Musculoskeletal discomfort (Side Effect) and Musculoskeletal discomfort (Side Effect) is caused by Amprenavir (Compound) and Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Paroxetine (Compound) causes Musculoskeletal discomfort (Side Effect) and Musculoskeletal discomfort (Side Effect) is caused by Cabazitaxel (Compound) and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Paroxetine (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Ticlopidine (Compound) and Ticlopidine may lead to a major life threatening interaction when taken with Trastuzumab emtansine
Paroxetine (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Regorafenib (Compound) and Regorafenib may lead to a major life threatening interaction when taken with Trastuzumab emtansine
Paroxetine (Compound) causes Transaminases increased (Side Effect) and Transaminases increased (Side Effect) is caused by Apixaban (Compound) and Apixaban may lead to a major life threatening interaction when taken with Trastuzumab emtansine
Paroxetine (Compound) causes Myositis (Side Effect) and Myositis (Side Effect) is caused by Ticlopidine (Compound) and Ticlopidine may lead to a major life threatening interaction when taken with Trastuzumab emtansine
Paroxetine (Compound) upregulates TSC22D3 (Gene) and TSC22D3 (Gene) is upregulated by Ketorolac (Compound) and Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Paroxetine (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is downregulated by Auranofin (Compound) and Auranofin may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine